Combined cediranib and olaparib presents similar activity to standard of care treatment
(NRG Oncology) Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer;, however, activity between the treatments were similar in patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Ovarian Cancer | Ovaries | Women